Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
详细信息 查看全文
- 作者：Avery D. Posey Jr.1 ; aposey@mail.med.upenn.edu" class="auth_mail" title="E-mail the corresponding author ; Robert D. Schwab1 ; Alina C. Boesteanu1 ; Catharina Steentoft2 ; Ulla Mandel2 ; Boris Engels3 ; 7 ; Jennifer D. Stone4 ; Thomas D. Madsen2 ; Karin Schreiber3 ; Kathleen M. Haines1 ; Alexandria P. Cogdill1 ; Taylor J. Chen1 ; Decheng Song1 ; John Scholler1 ; David M. Kranz4 ; Michael D. Feldman5 ; Regina Young1 ; Brian Keith1 ; Hans Schreiber3 ; Henrik Clausen2 ; Laura A. Johnson1 ; 5 ; 6 ; Carl H. June1 ; 5 ; 6 ; cjune@exchange.upenn.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Immunity
- 出版年：2016
- 出版时间：21 June 2016
- 年：2016
- 卷：44
- 期：6
- 页码：1444-1454
- 全文大小：4289 K
文摘
- •
Cancer cells of many tissues express an abnormal glycoform of MUC1, Tn-MUC1
- •
Normal human tissue does not express detectable Tn-MUC1 on the cellular surface
- •
CAR T cells are engineered to target Tn-MUC1 lyse tumor cells in vitro and in vivo
- •
Abnormal glycoform epitopes are valid clinical targets for CAR T cells